PUBLISHER: KBV Research | PRODUCT CODE: 1245509
PUBLISHER: KBV Research | PRODUCT CODE: 1245509
LAMEA Onychomycosis Market Size, Share & Industry Trends Analysis Report By Type (Distal Subungual, Proximal Subungual, White Superficial and Others), By Treatment (Topical, Oral and Others), By Country and Growth Forecast, 2022 - 2028
The Latin America, Middle East and Africa Onychomycosis Market would witness market growth of 7.1% CAGR during the forecast period (2022-2028).
The rise in the use of prosthetic devices, broad-spectrum antibiotics, and immunosuppressive and anti-cancer drugs has led to an increase in the frequency of fungus infections. The immune system gradually becomes less effective as people age.
As a result, age-related physical and cognitive changes frequently increase an individual's risk of contracting diseases like onychomycosis. Drugs continue to be the first-line therapeutic option for onychomycosis treatment and hold a significant market share due to a continuously high success rate. Terbinafine, ciclopirox, Penlac, ciclodan, Jublia, Fluconazole, ketoconazole, Sporanox, efinaconazole, griseofulvin, Itraconazole, Kerydin, and others are some of the prominent medications used to treat onychomycosis.
Over the past two decades, invasive fungal infections (IFIs) have become more pathogenic in Latin America. Clinicians and scientists have started to delve deeper into the mechanisms of disease and their connections to susceptible populations as diagnostic tools have advanced. The percentage of patients having an immunosuppressive state (hematopoietic stem cell transplantation [HSCT], HIV, autoimmune diseases) has dramatically increased. As the susceptibility to infection rises in the region, the demand for treatment of those infections would increase significantly. This, in turn, may increase the demand for onychomycosis treatment.
The Brazil market dominated the LAMEA Onychomycosis Market by Country in 2021, and would continue to be a dominant market till 2028; thereby, achieving a market value of $68.4 Million by 2028. The Argentina market is experiencing a CAGR of 7.6% during (2022 - 2028). Additionally, The UAE market would display a CAGR of 6.8% during (2022 - 2028).
Based on Type, the market is segmented into Distal Subungual, Proximal Subungual, White Superficial and Others. Based on Treatment, the market is segmented into Topical, Oral and Others. Based on countries, the market is segmented into Brazil, Argentina, UAE, Saudi Arabia, South Africa, Nigeria, and Rest of LAMEA.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Pfizer, Inc., Teva Pharmaceuticals Industries Ltd., Abbott Laboratories, Bausch Health Companies, Inc., Bayer AG, Cipla Limited, Merck & Co., Inc., Novartis AG, Sun Pharmaceutical Industries Ltd., and GlaxoSmithKline PLC.
Scope of the Study
Market Segments covered in the Report:
By Type
- Distal Subungual
- Proximal Subungual
- White Superficial
- Others
By Treatment
- Topical
- Oral
- Others
By Country
- Brazil
- Argentina
- UAE
- Saudi Arabia
- South Africa
- Nigeria
- Rest of LAMEA
Companies Profiled
- Pfizer, Inc.
- Teva Pharmaceuticals Industries Ltd.
- Abbott Laboratories
- Bausch Health Companies, Inc.
- Bayer AG
- Cipla Limited
- Merck & Co., Inc.
- Novartis AG
- Sun Pharmaceutical Industries Ltd.
- GlaxoSmithKline PLC
Unique Offerings from KBV Research
- Exhaustive coverage
- Highest number of market tables and figures
- Subscription based model available
- Guaranteed best price
- Assured post sales research support with 10% customization free
Table of Contents
Chapter 1. Market Scope & Methodology
- 1.1 Market Definition
- 1.2 Objectives
- 1.3 Market Scope
- 1.4 Segmentation
- 1.4.1 LAMEA Onychomycosis Market, by Type
- 1.4.2 LAMEA Onychomycosis Market, by Treatment
- 1.4.3 LAMEA Onychomycosis Market, by Country
- 1.5 Methodology for the research
Chapter 2. Market Overview
- 2.1 Introduction
- 2.1.1 Overview
- 2.1.1.1 Market Composition & Scenario
- 2.1.1 Overview
- 2.2 Key Factors Impacting the Market
- 2.2.1 Market Drivers
- 2.2.2 Market Restraints
Chapter 3. LAMEA Onychomycosis Market by Type
- 3.1 LAMEA Distal Subungual Market by Country
- 3.2 LAMEA Proximal Subungual Market by Country
- 3.3 LAMEA White Superficial Market by Country
- 3.4 LAMEA Others Market by Country
Chapter 4. LAMEA Onychomycosis Market by Treatment
- 4.1 LAMEA Topical Market by Country
- 4.2 LAMEA Oral Market by Country
- 4.3 LAMEA Others Market by Country
Chapter 5. LAMEA Onychomycosis Market by Country
- 5.1 Brazil Onychomycosis Market
- 5.1.1 Brazil Onychomycosis Market by Type
- 5.1.2 Brazil Onychomycosis Market by Treatment
- 5.2 Argentina Onychomycosis Market
- 5.2.1 Argentina Onychomycosis Market by Type
- 5.2.2 Argentina Onychomycosis Market by Treatment
- 5.3 UAE Onychomycosis Market
- 5.3.1 UAE Onychomycosis Market by Type
- 5.3.2 UAE Onychomycosis Market by Treatment
- 5.4 Saudi Arabia Onychomycosis Market
- 5.4.1 Saudi Arabia Onychomycosis Market by Type
- 5.4.2 Saudi Arabia Onychomycosis Market by Treatment
- 5.5 South Africa Onychomycosis Market
- 5.5.1 South Africa Onychomycosis Market by Type
- 5.5.2 South Africa Onychomycosis Market by Treatment
- 5.6 Nigeria Onychomycosis Market
- 5.6.1 Nigeria Onychomycosis Market by Type
- 5.6.2 Nigeria Onychomycosis Market by Treatment
- 5.7 Rest of LAMEA Onychomycosis Market
- 5.7.1 Rest of LAMEA Onychomycosis Market by Type
- 5.7.2 Rest of LAMEA Onychomycosis Market by Treatment
Chapter 6. Company Profiles
- 6.1 Abbott Laboratories
- 6.1.1 Company Overview
- 6.1.2 Financial Analysis
- 6.1.3 Segmental and Regional Analysis
- 6.1.4 Research & Development Expense
- 6.1.5 SWOT Analysis
- 6.2 Bausch Health Companies, Inc.
- 6.2.1 Company Overview
- 6.2.2 Financial Analysis
- 6.2.3 Segmental and Regional Analysis
- 6.2.4 Research & Development Expense
- 6.2.5 Recent strategies and developments:
- 6.2.5.1 Trials and Approvals:
- 6.3 Bayer AG
- 6.3.1 Company Overview
- 6.3.2 Financial Analysis
- 6.3.3 Segmental and Regional Analysis
- 6.3.4 Research & Development Expense
- 6.3.5 Recent strategies and developments:
- 6.3.5.1 Product Launches and Expansions:
- 6.4 Cipla Limited
- 6.4.1 Company Overview
- 6.4.2 Financial Analysis
- 6.4.3 Regional Analysis
- 6.4.4 Research & Development Expense
- 6.4.5 Recent strategies and developments:
- 6.4.5.1 Product Launches and Product Expansions:
- 6.5 Sun Pharmaceutical Industries Ltd.
- 6.5.1 Company Overview
- 6.5.2 Financial Analysis
- 6.5.3 Regional & Segmental Analysis
- 6.5.4 Research & Development Expenses
- 6.5.5 Recent strategies and developments:
- 6.5.5.1 Acquisition and Mergers:
- 6.6 GlaxoSmithKline PLC (GSK)
- 6.6.1 Company Overview
- 6.6.2 Financial Analysis
- 6.6.3 Segmental and Regional Analysis
- 6.6.4 Research & Development Expense
- 6.6.5 Recent strategies and developments:
- 6.6.5.1 Partnerships, Collaborations, and Agreements:
- 6.7 Pfizer, Inc.
- 6.7.1 Company Overview
- 6.7.2 Financial Analysis
- 6.7.3 Regional & Segmental Analysis
- 6.7.4 Research & Development Expense
- 6.8 Teva Pharmaceutical Industries Ltd.
- 6.8.1 Company Overview
- 6.8.2 Financial Analysis
- 6.8.3 Regional Analysis
- 6.8.4 Research & Development Expenses
- 6.9 Merck & Co., Inc.
- 6.9.1 Company Overview
- 6.9.2 Financial Analysis
- 6.9.3 Segmental and Regional Analysis
- 6.9.4 Research & Development Expenses
- 6.10. Novartis AG
- 6.10.1 Company Overview
- 6.10.2 Financial Analysis
- 6.10.3 Segmental and Regional Analysis
- 6.10.4 Research & Development Expense
LIST OF TABLES
- TABLE 1 LAMEA Onychomycosis Market, 2018 - 2021, USD Million
- TABLE 2 LAMEA Onychomycosis Market, 2022 - 2028, USD Million
- TABLE 3 LAMEA Onychomycosis Market by Type, 2018 - 2021, USD Million
- TABLE 4 LAMEA Onychomycosis Market by Type, 2022 - 2028, USD Million
- TABLE 5 LAMEA Distal Subungual Market by Country, 2018 - 2021, USD Million
- TABLE 6 LAMEA Distal Subungual Market by Country, 2022 - 2028, USD Million
- TABLE 7 LAMEA Proximal Subungual Market by Country, 2018 - 2021, USD Million
- TABLE 8 LAMEA Proximal Subungual Market by Country, 2022 - 2028, USD Million
- TABLE 9 LAMEA White Superficial Market by Country, 2018 - 2021, USD Million
- TABLE 10 LAMEA White Superficial Market by Country, 2022 - 2028, USD Million
- TABLE 11 LAMEA Others Market by Country, 2018 - 2021, USD Million
- TABLE 12 LAMEA Others Market by Country, 2022 - 2028, USD Million
- TABLE 13 LAMEA Onychomycosis Market by Treatment, 2018 - 2021, USD Million
- TABLE 14 LAMEA Onychomycosis Market by Treatment, 2022 - 2028, USD Million
- TABLE 15 LAMEA Topical Market by Country, 2018 - 2021, USD Million
- TABLE 16 LAMEA Topical Market by Country, 2022 - 2028, USD Million
- TABLE 17 LAMEA Oral Market by Country, 2018 - 2021, USD Million
- TABLE 18 LAMEA Oral Market by Country, 2022 - 2028, USD Million
- TABLE 19 LAMEA Others Market by Country, 2018 - 2021, USD Million
- TABLE 20 LAMEA Others Market by Country, 2022 - 2028, USD Million
- TABLE 21 LAMEA Onychomycosis Market by Country, 2018 - 2021, USD Million
- TABLE 22 LAMEA Onychomycosis Market by Country, 2022 - 2028, USD Million
- TABLE 23 Brazil Onychomycosis Market, 2018 - 2021, USD Million
- TABLE 24 Brazil Onychomycosis Market, 2022 - 2028, USD Million
- TABLE 25 Brazil Onychomycosis Market by Type, 2018 - 2021, USD Million
- TABLE 26 Brazil Onychomycosis Market by Type, 2022 - 2028, USD Million
- TABLE 27 Brazil Onychomycosis Market by Treatment, 2018 - 2021, USD Million
- TABLE 28 Brazil Onychomycosis Market by Treatment, 2022 - 2028, USD Million
- TABLE 29 Argentina Onychomycosis Market, 2018 - 2021, USD Million
- TABLE 30 Argentina Onychomycosis Market, 2022 - 2028, USD Million
- TABLE 31 Argentina Onychomycosis Market by Type, 2018 - 2021, USD Million
- TABLE 32 Argentina Onychomycosis Market by Type, 2022 - 2028, USD Million
- TABLE 33 Argentina Onychomycosis Market by Treatment, 2018 - 2021, USD Million
- TABLE 34 Argentina Onychomycosis Market by Treatment, 2022 - 2028, USD Million
- TABLE 35 UAE Onychomycosis Market, 2018 - 2021, USD Million
- TABLE 36 UAE Onychomycosis Market, 2022 - 2028, USD Million
- TABLE 37 UAE Onychomycosis Market by Type, 2018 - 2021, USD Million
- TABLE 38 UAE Onychomycosis Market by Type, 2022 - 2028, USD Million
- TABLE 39 UAE Onychomycosis Market by Treatment, 2018 - 2021, USD Million
- TABLE 40 UAE Onychomycosis Market by Treatment, 2022 - 2028, USD Million
- TABLE 41 Saudi Arabia Onychomycosis Market, 2018 - 2021, USD Million
- TABLE 42 Saudi Arabia Onychomycosis Market, 2022 - 2028, USD Million
- TABLE 43 Saudi Arabia Onychomycosis Market by Type, 2018 - 2021, USD Million
- TABLE 44 Saudi Arabia Onychomycosis Market by Type, 2022 - 2028, USD Million
- TABLE 45 Saudi Arabia Onychomycosis Market by Treatment, 2018 - 2021, USD Million
- TABLE 46 Saudi Arabia Onychomycosis Market by Treatment, 2022 - 2028, USD Million
- TABLE 47 South Africa Onychomycosis Market, 2018 - 2021, USD Million
- TABLE 48 South Africa Onychomycosis Market, 2022 - 2028, USD Million
- TABLE 49 South Africa Onychomycosis Market by Type, 2018 - 2021, USD Million
- TABLE 50 South Africa Onychomycosis Market by Type, 2022 - 2028, USD Million
- TABLE 51 South Africa Onychomycosis Market by Treatment, 2018 - 2021, USD Million
- TABLE 52 South Africa Onychomycosis Market by Treatment, 2022 - 2028, USD Million
- TABLE 53 Nigeria Onychomycosis Market, 2018 - 2021, USD Million
- TABLE 54 Nigeria Onychomycosis Market, 2022 - 2028, USD Million
- TABLE 55 Nigeria Onychomycosis Market by Type, 2018 - 2021, USD Million
- TABLE 56 Nigeria Onychomycosis Market by Type, 2022 - 2028, USD Million
- TABLE 57 Nigeria Onychomycosis Market by Treatment, 2018 - 2021, USD Million
- TABLE 58 Nigeria Onychomycosis Market by Treatment, 2022 - 2028, USD Million
- TABLE 59 Rest of LAMEA Onychomycosis Market, 2018 - 2021, USD Million
- TABLE 60 Rest of LAMEA Onychomycosis Market, 2022 - 2028, USD Million
- TABLE 61 Rest of LAMEA Onychomycosis Market by Type, 2018 - 2021, USD Million
- TABLE 62 Rest of LAMEA Onychomycosis Market by Type, 2022 - 2028, USD Million
- TABLE 63 Rest of LAMEA Onychomycosis Market by Treatment, 2018 - 2021, USD Million
- TABLE 64 Rest of LAMEA Onychomycosis Market by Treatment, 2022 - 2028, USD Million
- TABLE 65 Key Information - Abbott Laboratories
- TABLE 66 key information - Bausch Health Companies, Inc.
- TABLE 67 Key Information - Bayer AG
- TABLE 68 Key Information - Cipla Limited
- TABLE 69 Key Information - Sun Pharmaceutical Industries Ltd.
- TABLE 70 Key Information - GlaxoSmithKline PLC (GSK)
- TABLE 71 Key Information - Pfizer, Inc.
- TABLE 72 Key Information - Teva Pharmaceuticals Industries Ltd.
- TABLE 73 KEY INFORMATION - Merck & Co., Inc.
- TABLE 74 Key Information - Novartis AG
List of Figures
- FIG 1 Methodology for the research
- FIG 2 Swot analysis: Abbott laboratories
